查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1635875

2025-2033年嬰兒痙攣治療市場依治療類別、藥物類型（氨己烯酸、促腎上腺皮質激素等）、劑量、給藥途徑、配銷通路、最終用戶和地區

Infantile Spasms Therapeutics Market by Therapeutic Class, Drug Type (Vigabatrin, Adrenocorticotropic Hormone, and Others ), Dosage, Route of Administration, Distribution Channel, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 128 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球嬰兒IMARC Group症治療市場規模達38億美元。嬰兒癲癇發作的盛行率不斷上升、大眾健康意識的提高導致早期診斷、產品批准數量的增加以及強大的管道藥物的存在是推動市場的一些關鍵因素。

嬰兒痙攣療法是指用於治療幼兒癲癇發作或癲癇症候群的治療程序，幼兒通常年齡在四個月到一歲之間。痙攣發作的特徵是身體突然僵硬，手臂、腿和頭部向前彎曲，背部拱起，以及短暫而微妙的癲癇發作。嬰兒痙攣症可由腦腫瘤、出生損傷、腦部感染和基因改變引起。針對嬰兒垃圾郵件有多種治療選擇，包括類固醇、促腎上腺皮質激素注射凝膠和糖皮質激素的荷爾蒙療法以及抗癲癇藥物。如果在痙攣發生後三週內實施嬰兒痙攣症治療，則更有可能提供持續的效果，並且可以透過單一療法或合併療法進行治療。嬰兒痙攣症可透過身體檢查、神經系統檢查、腦部 MRI 以及血液和尿液檢查來診斷。

嬰兒痙攣症治療市場趨勢：

新生兒中嬰兒痙攣症盛行率的增加是推動市場成長的重要因素。這可以歸因於全球出生率的大幅上升。與此一致的是，越來越多的產品批准和強大的管道藥物的存在正在對市場產生積極影響。嬰兒痙攣症治療的持續技術進步，例如引入用於檢測癲癇發作並提醒護理人員的癲癇警報裝置，正在為市場提供動力。此外，人們對早期診斷和治療的廣泛認知正在提高嬰兒痙攣症藥物的滲透率，從而推動市場成長。然而，各種因素，例如治療成功率較低、治療成本較高、藥物核准的嚴格規定以及未確診患者數量的增加，正在阻礙嬰兒痙攣症治療市場的成長。相反，一些國家的政府和私人組織為提高人們對醫療狀況的認知而採取的有利舉措和計劃正在創造積極的市場前景。主要市場參與者所進行的廣泛研發（R＆D）活動進一步推動了市場的發展，這些活動專注於開發成功率更高的創新藥物。影響市場的其他一些因素包括不斷擴大的醫療保健支出、不斷增加的合作、夥伴關係和併購 (M&A)、快速城市化以及可支配收入水平的提高。

本報告回答的關鍵問題

  • 全球嬰兒痙攣症治療市場有多大？ 2025-2033年全球嬰兒痙攣症治療市場的預期成長率是多少？
  • 推動全球嬰兒痙攣症治療市場的關鍵因素是什麼？
  • COVID-19 對全球嬰兒痙攣症治療市場有何影響？
  • 根據治療類別，全球嬰兒痙攣症治療市場的細分如何？
  • 根據藥物類型，全球嬰兒痙攣症治療市場的細分如何？
  • 根據劑量，全球嬰兒痙攣症治療市場的細分如何？
  • 根據給藥途徑，全球嬰兒痙攣症治療市場的細分如何？
  • 基於配銷通路的全球嬰兒痙攣症治療市場的詳細情形如何？
  • 基於最終用戶的全球嬰兒痙攣症治療市場的詳細情形如何？
  • 全球嬰兒痙攣症治療市場的關鍵地區有哪些？
  • 誰是全球嬰兒痙攣症治療市場的主要參與者/公司？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 數據來源
    • 主要來源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球嬰兒痙攣症治療市場

  • 市場概況
  • 市場表現
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依治療類別

  • 抗驚厥藥
    • 市場趨勢
    • 市場預測
  • 皮質類固醇
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 7 章：市場區隔：依藥物類型

  • 氨己烯酸
    • 市場趨勢
    • 市場預測
  • 促腎上腺皮質激素
    • 市場趨勢
    • 市場預測
  • 其他（三期）
    • 市場趨勢
    • 市場預測

第 8 章：市場區隔：按劑量

  • 堅硬的
    • 市場趨勢
    • 市場預測
  • 液體
    • 市場趨勢
    • 市場預測

第 9 章：市場區隔：依管理途徑

  • 口服
    • 市場趨勢
    • 市場預測
  • 注射用
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 10 章：市場區隔：按配銷通路

  • 醫院藥房
    • 市場趨勢
    • 市場預測
  • 零售藥房
    • 市場趨勢
    • 市場預測
  • 網路藥房
    • 市場趨勢
    • 市場預測

第 11 章：市場區隔：依最終用戶

  • 醫院
    • 市場趨勢
    • 市場預測
  • 診所
    • 市場趨勢
    • 市場預測
  • 其他
    • 市場趨勢
    • 市場預測

第 12 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲
    • 市場趨勢
    • 市場細分：按國家/地區
    • 市場預測

第 13 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 14 章：價值鏈分析

第 15 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 16 章：價格分析

第17章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • H. Lundbeck A/S
    • Mallinckrodt plc
    • ORPHELIA Pharma
    • Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
Product Code: SR112025A6789

The global infantile spasms therapeutics market size reached USD 3.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.2 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The rising prevalence of seizures in infants, increasing health consciousness among the masses resulting in early diagnosis, and the growing number of product approvals and presence of strong pipelines drugs represent some of the key factors driving the market.

Infantile spasms therapeutics refer to the treatment procedures used for treating seizures or an epilepsy syndrome in young children, usually aged between four months and a year of age. An episode of spasm is characterized by the body stiffening suddenly, arms, legs, and head bending forward, the back arching, and short, subtle seizures. Infantile spasm can be caused by brain tumors, birth injuries, infection of the brain, and genetic changes. There are a number of therapeutic options that are available for infantile spams, including steroids, hormone therapy with corticotropin injection gel and glucocorticoids, as well as antiseizure medications. Infantile spasms therapeutics are more likely to provide sustained results if they are implemented within three weeks after the spasms occur, and treatment can be done by monotherapy or combination therapy. Infantile spasms are diagnosed by physical examination, neurological examination, MRI of the brain, and blood and urine examinations.

Infantile Spasms Therapeutics Market Trends:

The increasing prevalence of infantile spasms among newborn babies is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the birth rates across the globe. In line with this, the growing number of product approvals and presence of strong pipelines drugs are impacting the market positively. Continual technological advancements in the treatment of infantile spasms, such as the introduction of seizure alert device for detecting seizures and alerting the caregivers, are providing an impetus to the market. Also, the widespread awareness regarding early diagnosis and treatment is enhancing the penetration rate of infantile spasm drugs, thereby fueling the market growth. However, various factors, such as lesser treatment success rates, high cost of treatment, strict regulations for drug approval, and the augmenting undiagnosed patient pool, are impeding the growth of the infantile spasms therapeutics market. On the contrary, favorable initiatives and programs conducted by the government and private organizations of several countries for promoting awareness regarding the medical condition is creating a positive market outlook. The market is further driven by the extensive research and development (R&D) activities conducted by the key market players focusing on the development of innovative drugs with higher success rates. Some of the other factors contributing to the market include the expanding healthcare expenditure, rising number of collaborations, partnerships and merger and acquisitions (M&As), rapid urbanization, and inflating disposable income levels.

Key Market Segmentation:

Therapeutic Class Insights:

  • Anticonvulsants
  • Corticosteroids
  • Others

Drug Type Insights:

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others (Phase III)

Dosage Insights:

  • Solid
  • Liquid

Route of Administration Insights:

  • Oral
  • Parenteral
  • Others

Distribution Channel Insights:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

End User Insights:

  • Hospitals
  • Clinics
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for infantile spasms therapeutics. Some of the factors driving the North America infantile spasms therapeutics market include the presence of several key players, inflating disposable income levels, and the widespread awareness regarding early disease diagnosis and prevention.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global infantile spasms therapeutics market. Detailed profiles of all major companies have also been provided. Some of the companies covered include H. Lundbeck A/S, Mallinckrodt plc, ORPHELIA Pharma, Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global infantile spasms therapeutics market?
  • 2. What is the expected growth rate of the global infantile spasms therapeutics market during 2025-2033?
  • 3. What are the key factors driving the global infantile spasms therapeutics market?
  • 4. What has been the impact of COVID-19 on the global infantile spasms therapeutics market?
  • 5. What is the breakup of the global infantile spasms therapeutics market based on the therapeutic class?
  • 6. What is the breakup of the global infantile spasms therapeutics market based on the drug type?
  • 7. What is the breakup of the global infantile spasms therapeutics market based on the dosage?
  • 8. What is the breakup of the global infantile spasms therapeutics market based on route of administration?
  • 9. What is the breakup of the global infantile spasms therapeutics market based on the distribution channel?
  • 10. What is the breakup of the global infantile spasms therapeutics market based on the end user?
  • 11. What are the key regions in the global infantile spasms therapeutics market?
  • 12. Who are the key players/companies in the global infantile spasms therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Infantile Spasms Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapeutic Class

  • 6.1 Anticonvulsants
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Corticosteroids
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Vigabatrin
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Adrenocorticotropic Hormone
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others (Phase III)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Dosage

  • 8.1 Solid
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Liquid
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Route of Administration

  • 9.1 Oral
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Parenteral
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacy
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacy
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacy
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast

11 Market Breakup by End User

  • 11.1 Hospitals
    • 11.1.1 Market Trends
    • 11.1.2 Market Forecast
  • 11.2 Clinics
    • 11.2.1 Market Trends
    • 11.2.2 Market Forecast
  • 11.3 Others
    • 11.3.1 Market Trends
    • 11.3.2 Market Forecast

12 Market Breakup by Region

  • 12.1 North America
    • 12.1.1 United States
      • 12.1.1.1 Market Trends
      • 12.1.1.2 Market Forecast
    • 12.1.2 Canada
      • 12.1.2.1 Market Trends
      • 12.1.2.2 Market Forecast
  • 12.2 Asia-Pacific
    • 12.2.1 China
      • 12.2.1.1 Market Trends
      • 12.2.1.2 Market Forecast
    • 12.2.2 Japan
      • 12.2.2.1 Market Trends
      • 12.2.2.2 Market Forecast
    • 12.2.3 India
      • 12.2.3.1 Market Trends
      • 12.2.3.2 Market Forecast
    • 12.2.4 South Korea
      • 12.2.4.1 Market Trends
      • 12.2.4.2 Market Forecast
    • 12.2.5 Australia
      • 12.2.5.1 Market Trends
      • 12.2.5.2 Market Forecast
    • 12.2.6 Indonesia
      • 12.2.6.1 Market Trends
      • 12.2.6.2 Market Forecast
    • 12.2.7 Others
      • 12.2.7.1 Market Trends
      • 12.2.7.2 Market Forecast
  • 12.3 Europe
    • 12.3.1 Germany
      • 12.3.1.1 Market Trends
      • 12.3.1.2 Market Forecast
    • 12.3.2 France
      • 12.3.2.1 Market Trends
      • 12.3.2.2 Market Forecast
    • 12.3.3 United Kingdom
      • 12.3.3.1 Market Trends
      • 12.3.3.2 Market Forecast
    • 12.3.4 Italy
      • 12.3.4.1 Market Trends
      • 12.3.4.2 Market Forecast
    • 12.3.5 Spain
      • 12.3.5.1 Market Trends
      • 12.3.5.2 Market Forecast
    • 12.3.6 Russia
      • 12.3.6.1 Market Trends
      • 12.3.6.2 Market Forecast
    • 12.3.7 Others
      • 12.3.7.1 Market Trends
      • 12.3.7.2 Market Forecast
  • 12.4 Latin America
    • 12.4.1 Brazil
      • 12.4.1.1 Market Trends
      • 12.4.1.2 Market Forecast
    • 12.4.2 Mexico
      • 12.4.2.1 Market Trends
      • 12.4.2.2 Market Forecast
    • 12.4.3 Others
      • 12.4.3.1 Market Trends
      • 12.4.3.2 Market Forecast
  • 12.5 Middle East and Africa
    • 12.5.1 Market Trends
    • 12.5.2 Market Breakup by Country
    • 12.5.3 Market Forecast

13 Drivers, Restraints, and Opportunities

  • 13.1 Overview
  • 13.2 Drivers
  • 13.3 Restraints
  • 13.4 Opportunities

14 Value Chain Analysis

15 Porters Five Forces Analysis

  • 15.1 Overview
  • 15.2 Bargaining Power of Buyers
  • 15.3 Bargaining Power of Suppliers
  • 15.4 Degree of Competition
  • 15.5 Threat of New Entrants
  • 15.6 Threat of Substitutes

16 Price Analysis

17 Competitive Landscape

  • 17.1 Market Structure
  • 17.2 Key Players
  • 17.3 Profiles of Key Players
    • 17.3.1 H. Lundbeck A/S
      • 17.3.1.1 Company Overview
      • 17.3.1.2 Product Portfolio
      • 17.3.1.3 Financials
      • 17.3.1.4 SWOT Analysis
    • 17.3.2 Mallinckrodt plc
      • 17.3.2.1 Company Overview
      • 17.3.2.2 Product Portfolio
      • 17.3.2.3 Financials
    • 17.3.3 ORPHELIA Pharma
      • 17.3.3.1 Company Overview
      • 17.3.3.2 Product Portfolio
    • 17.3.4 Teva Pharmaceuticals USA Inc. (Teva Pharmaceutical Industries Ltd.)
      • 17.3.4.1 Company Overview
      • 17.3.4.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

  • Figure 1: Global: Infantile Spasms Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Infantile Spasms Therapeutics Market: Breakup by Therapeutic Class (in %), 2024
  • Figure 5: Global: Infantile Spasms Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 6: Global: Infantile Spasms Therapeutics Market: Breakup by Dosage (in %), 2024
  • Figure 7: Global: Infantile Spasms Therapeutics Market: Breakup by Route of Administration (in %), 2024
  • Figure 8: Global: Infantile Spasms Therapeutics Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Infantile Spasms Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 10: Global: Infantile Spasms Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 11: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Infantile Spasms Therapeutics (Anticonvulsants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Infantile Spasms Therapeutics (Corticosteroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Infantile Spasms Therapeutics (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Infantile Spasms Therapeutics (Other Therapeutic Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Infantile Spasms Therapeutics (Vigabatrin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Infantile Spasms Therapeutics (Vigabatrin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Infantile Spasms Therapeutics (Adrenocorticotropic Hormone) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Infantile Spasms Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Infantile Spasms Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Infantile Spasms Therapeutics (Solid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Infantile Spasms Therapeutics (Solid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Infantile Spasms Therapeutics (Liquid) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Infantile Spasms Therapeutics (Liquid) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Infantile Spasms Therapeutics (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Infantile Spasms Therapeutics (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Infantile Spasms Therapeutics (Parenteral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Infantile Spasms Therapeutics (Parenteral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Infantile Spasms Therapeutics (Other Routes of Administration) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Infantile Spasms Therapeutics (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Infantile Spasms Therapeutics (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Infantile Spasms Therapeutics (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Infantile Spasms Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Infantile Spasms Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Infantile Spasms Therapeutics (Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Infantile Spasms Therapeutics (Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Infantile Spasms Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Infantile Spasms Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: North America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: North America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: United States: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: United States: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Canada: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Canada: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Asia-Pacific: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Asia-Pacific: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: China: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: China: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Japan: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Japan: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: India: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: India: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: South Korea: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: South Korea: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Australia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Australia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Indonesia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Indonesia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Europe: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Europe: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Germany: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Germany: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: France: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: France: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: United Kingdom: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: United Kingdom: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Italy: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Italy: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Spain: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Spain: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Russia: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Russia: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Latin America: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Latin America: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Brazil: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Brazil: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Mexico: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Mexico: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Others: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Others: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Middle East and Africa: Infantile Spasms Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Middle East and Africa: Infantile Spasms Therapeutics Market: Breakup by Country (in %), 2024
  • Figure 93: Middle East and Africa: Infantile Spasms Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Global: Infantile Spasms Therapeutics Industry: Drivers, Restraints, and Opportunities
  • Figure 95: Global: Infantile Spasms Therapeutics Industry: Value Chain Analysis
  • Figure 96: Global: Infantile Spasms Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Infantile Spasms Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Therapeutic Class (in Million USD), 2025-2033
  • Table 3: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Dosage (in Million USD), 2025-2033
  • Table 5: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 6: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 8: Global: Infantile Spasms Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 9: Global: Infantile Spasms Therapeutics Market: Competitive Structure
  • Table 10: Global: Infantile Spasms Therapeutics Market: Key Players